• European Commission grants EU marketing authorization for Zealand Pharma’s Zeydovio (glepaglutide) to treat adults with short bowel syndrome.
• The company is seeking a partner for global commercialization; a Phase 3 trial supporting US registration is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130958PRIMZONEFULLFEED1001303531) on November 13, 2026, and is solely responsible for the information contained therein.